Myriad - geht´s wieder aufwärts?

       
     

Nach mustergültiger Bodenbildung und zunehmend positivem Newsflow scheint nun
endlich der Ausbruch nach oben anzustehen. Gestern hat sich die Aktie in USA nach Bekanntgabe einer Kooperation mit Abbott unter hohem Volumen aus einer hartnäckigen Widerstandszone endgültig gelöst. Ich denke, Myriad hat einiges nachzuholen! Fundamental steht das Unternehmen gut da, Cash ist reichlich vorhanden, die Pipeline reift zusehends und der stetige Cashflow aus dem Nischen-Geschäft mit Gen-Diagnostica wird auch nicht schmäler.

Was halten andere hier von meinem Liebling?

Gruß,
sertralin19


 

Myriad Genetics (ticker: MYGN, exchange: NASDAQ) News Release - 13-Jan-2004


--------------------------------------------------
Myriad Genetics' Cancer Drug Candidate MPI-176716 Causes Ovarian Tumor Remission

SALT LAKE CITY, Jan. 13 /PRNewswire-FirstCall/ -- Myriad Genetics, Inc. (Nasdaq: MYGN), today announced progress with its anti-cancer compound, MPI-176716. The drug candidate is in the final stages of preclinical development prior to submission to the FDA as an Investigational New Drug (IND). The new data released by the Company demonstrates the drug's exceptional potency in killing cancer cells and its ability to cause tumor regression in animal models of ovarian cancer.

MPI-176716 was tested against OVCAR tumor cells in a mouse xenograft model. Myriad's drug candidate was evaluated in comparison to the current standard of care in ovarian cancer therapy, carboplatin. MPI-176716 was given to the mice in combination with carboplatin, using saline as control. Compared with saline control, carboplatin alone reduced tumor volume by approximately 20%, a significant achievement against this notoriously difficult tumor. But remarkably, when MPI-176716 was combined with carboplatin, the tumors were sent into remission, regressing essentially 100% by the end of the trial. At the end of the 55 day study period, the MPI-176716 treated mice had an ending tumor volume that was below measurement range.

"We are excited by the potential of this promising drug candidate to treat a variety of cancer types," said Peter Meldrum, President and Chief Executive Officer of Myriad Genetics, Inc. "There are few options available to treat aggressive tumors such as ovarian cancer and we are not aware of any drug on the market that shows as great a level of activity against the OVCAR ovarian cancer tumor model. We intend to vigorously move this drug candidate into human clinical trials this year."

Myriad discovered the drug's anti-cancer target through the use of its proprietary genetics and protein interaction technologies. MPI-176716, a small molecule drug candidate, was discovered using Myriad's proprietary library of approximately 300,000 proprietary molecules, followed by a medicinal chemistry program. Myriad has formulated a preferred IV (intravenous) preparation of the drug candidate in preparation for human clinical trials.

MPI-176716 induces apoptosis in cancer cell lines. The drug candidate has demonstrated a good early safety profile. It has broad anti-cancer activity as established against a variety of solid tumors and blood cancers in culture.

MPI-176716 was tested in parallel with cisplatin and etoposide, two common anti-neoplastic compounds used to treat certain ovarian cancer, bladder cancer, lung cancer, testicular cancer and non-hodgkins lymphoma cases. MPI-176716 was more potent than either, killing cancer cells rapidly. It was 30 times more potent than Cisplatin and 20 times more potent than Etoposide.

Cancer is uncontrolled growth and spread of abnormal cells. Normal cells go through a programmed process of cell death called apoptosis, part of the body's constant effort to rejuvenate itself. Cancer cells have managed to avoid this process, and become immortal. MPI-176716 selectively induces apoptosis in cancer cells, causing them, in essence, to self-destruct.

Myriad Genetics, Inc. is a leading biopharmaceutical company focused on the development of novel healthcare products. The Company develops and markets proprietary predictive medicine and personalized medicine products, and is developing and intends to market a number of promising therapeutic products that address large potential markets. Myriad's news and other information are available on the Company's Web site at www.myriad.com .

Noch ist es nicht zu spät...

Grüße

sertralin19  

Myriad Genetics (ticker: MYGN, exchange: NASDAQ) News Release - 20-Jan-2004


--------------------------------------------------
Myriad Genetics' Cancer Compound MPC-6827 Causes Tumor Regression in Pancreatic Cancers

        - Data to Be Presented at Upcoming AACR Cancer Conference -
SALT LAKE CITY, Jan. 20 /PRNewswire-FirstCall/ -- Myriad Genetics, Inc. (Nasdaq: MYGN), today announced results of preclinical testing with its new pro-apoptotic compound, MPC-6827. This novel compound was discovered through the application of a caspase-based, high throughput screening system by Maxim Pharmaceuticals, Inc. and a subsequent medicinal chemistry program. Myriad is completing the toxicology, CMC and pharmacokinetic data required for submission to the FDA to register MPC-6827 as an Investigational New Drug (IND).

Myriad tested MPC-6827 against pancreatic tumors in a xenograft mouse model to mimic the human form of the disease. One group of mice was treated with 80 mg/kg of gemcitabine, the standard of care in pancreatic cancer chemotherapy, and the other group was treated with 5 mg/kg of MPC-6827. All treated mice showed statistically significant inhibition of tumor growth. However, MPC-6827 demonstrated a 38% inhibition of tumor growth, while gemcitabine showed just a 17% inhibition of tumor growth, compared with controls. In pancreatic tumors, the compound was twice as effective as gemcitabine, and achieved this improved efficacy at a significantly lower dose.

MPC-6827 also performed well in testing against other tumor types in xenograft models. In melanoma tumors, one group of mice was treated with 25 mg/kg of paclitaxel and the other group was treated with 5 mg/kg of MPC-6827. The activity of MPC-6827 was greater than that observed with paclitaxel. More significantly, MPC-6827 treated mice had twice the survival rate compared with the paclitaxel treated mice. At the conclusion of the study, 60% of the MPC-6827 treated mice had survived the cancer, versus only 30% for the paclitaxel treated group and just 10% of the controls. The improved survival with MPC-6827 treated mice versus the control animals achieved statistical significance at a value of p=0.0002.

In a breast cancer xenograft model, three groups of mice were given MPC-6827 at doses ranging from 5 mg/kg to 10 mg/kg. In each cohort of animals, MPC-6827 completely halted the progression of breast cancer tumors, while the untreated control mice experienced a 1000% increase in tumor size.

"As a cancer researcher and scientific advisor to cancer drug developers, I have reviewed the preclinical data of a great many compounds," said Daniel Von Hoff, M.D., Executive Vice President of the Translational Genomics Research Institute (TGen) and Director of the Cancer Therapeutics Program at the Arizona Health Sciences Center. "MPC-6827 is certainly the best preclinical candidate that I have seen in several years. Based on the remarkable efficacy data in cell-based and xenograft models, I feel confident that this molecule will be active in humans."

"We share Dr. Von Hoff's excitement about the potential of this promising new drug candidate," said Adrian Hobden, Ph.D., President of Myriad Pharmaceuticals, Inc. "It demonstrates a marked ability to cause tumor regression in animal models and shows strong activity against melanoma and

cancers of the ovary, breast, prostate, colon and pancreas. We are anxious to move this drug candidate into human clinical trials."

Cancer is uncontrolled growth and spread of abnormal cells. Normal cells go through a programmed process of cell death called apoptosis, part of the body's surveillance and defense mechanism against uncontrolled growth. Cancer cells manage to avoid this process, and become essentially immortal. MPC-6827 selectively induces apoptosis in cancer cells, causing them, in essence, to self-destruct. Myriad has several anti-cancer therapeutic development programs in process. MPC-6827 has a mechanism of action that is distinct from another advanced Myriad anti-cancer compound, MPI-176716. Both drug candidates appear effective in killing cancer cells and regressing tumors of many types, but they achieve their effect through different pathways.

Gruß

sertralin19
 

Myriad Genetics (ticker: MYGN, exchange: NASDAQ) News Release - 27-Jan-2004


--------------------------------------------------
Myriad Genetics Announces Second Quarter Results Conference Call; Tuesday, February 3, 2004 at 10:00 a.m. ET

SALT LAKE CITY--(BUSINESS WIRE)--Jan. 27, 2004--Myriad Genetics, Inc. (NASDAQ:MYGN) has arranged a conference call with the management team to provide a company update. Peter Meldrum, President and Chief Executive Officer, Jay Moyes, Chief Financial Officer, Jerry Lanchbury, Ph.D., Senior Vice President of Research, and Greg Critchfield, MD, President, Myriad Genetic Laboratories, Inc., will host the call.

                       DATE: February 3, 2004
                          TIME: 10:00 am ET
                  DOMESTIC DIAL-IN: (800) 245-3043
                INTERNATIONAL DIAL-IN: (785) 832-2041
           (Please dial in approximately 10 minutes before
                   the call is scheduled to begin)

    A press release will be issued at 6:30 am ET on February 3rd.
Replay of the call will be available for 7 days following the call at
                  (800) 934-2730 or (402) 220-1141.

         The call will also be available on the Internet at:
                           www.myriad.com

This call is being webcast by CCBN and can be accessed at Myriad's web site at www.myriad.com.

The webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at www.companyboardroom.com. Institutional investors can access the call via CCBN's password-protected event management site, StreetEvents (www.streetevents.com).


   CONTACT: Myriad Genetics
            Lori Farmer, 801-584-1138

   SOURCE: Myriad Genetics, Inc.

------------------------------------------------

Vielleicht werden da noch weitere kurstreibende News präsentiert? Der Chart schaut jedenfalls immer noch recht vielversprechend aus. Wird das etwa eine einjährige, große "ich bin am Boden angekommen"-W-Formation?!

Bleibe long, Grüße

sertralin19

P.S.:
Bin gespannt, wann der erste "Gastbeitrag" hier einläuft. Für mich jedenfalls eher ein positives Zeichen, dass sich derzeit noch niemand für meine geliebte (man soll sich ja eigentlich nicht in Aktien verlieben...) MYD interessiert.


 

ist selber Schuld:

       
     

Nach über 1 Jahr steht eine riesige W-Formation kurz vor Ihrer Vollendung. Alle gleitenden Durchschnitte sind unter hohem Volumen im Januar nach oben durchbrochen worden. Die Durchschnittslinien selbst haben ebenfalls alle nach oben gedreht.

Am Dienstag ist Q2-update. Sollte MYD über $18 schließen (obiger Chart ist in EURO, ist der Weg bis $25 erst mal frei. Dann könnte auch schnell noch mehr daraus werden...

gruß
sertralin19  

Myriad Genetics (ticker: MYGN, exchange: NASDAQ) News Release - 3-Feb-2004


--------------------------------------------------
Myriad Genetics Reports Results for Second Quarter of Fiscal 2004

- Predictive Medicine Revenues Increase 30% Over Prior Quarter, Gross Margins
                                Reach 67% -
SALT LAKE CITY, Feb. 3 /PRNewswire-FirstCall/ -- Myriad Genetics, Inc. (Nasdaq: MYGN) today reported financial results for the second quarter of fiscal 2004 and six months ended December 31, 2003.

For the second fiscal quarter ended December 31, 2003, predictive medicine revenues grew to a record $10.4 million, a 28% increase compared with the second fiscal quarter last year, which ended December 31, 2002, and a 30% increase compared with the first quarter of this current fiscal year, ended September 30, 2003. This significant increase in predictive medicine revenues resulted from strong customer demand for Myriad's predictive medicine products. For the first six months of this year, predictive medicine revenues increased to $18.5 million, from $16.0 million during the same period last year.

Gross profit margins on predictive medicine revenues also increased to a record 67% for the second quarter of fiscal 2004, compared with 63% for the same period last year. The growth in predictive medicine profit margins was primarily due to economies of scale resulting from wider acceptance of Myriad's predictive medicine products by consumers and the medical community and a number of technical improvements in the Company's high-throughput sequencing facility, including the automation of the previously labor- intensive DNA extraction step of the process.

Total revenues increased to $14.1 million for the second quarter of fiscal 2004, compared with $13.7 million in the first quarter of fiscal 2004. For the second quarter of the prior fiscal year, total revenues were $17.0 million. The decrease in total revenues compared with the same quarter in the prior year was due to a reduction in research revenues, reflecting the Company's enhanced focus on internal drug development programs and a corresponding reduction in emphasis on external collaborative research.

Net loss for the second quarter was $9.9 million or $0.36 per share, compared with $6.9 million, or $0.27 per share, for the same quarter of fiscal 2003. The increased loss was in line with the Company's planned increase in investment in internal drug development, primarily on its three human clinical trials currently in progress and on its three preclinical compounds in final preparation for future IND submission. As of December 31, 2003, Myriad had approximately $103 million in cash, cash equivalents and marketable investment securities.

"Myriad has achieved significant progress in advancing its therapeutic product development strategy," stated Peter Meldrum, President and CEO of Myriad Genetics, Inc. "MPC-7869 continues to impress us with its potential as a therapeutic for Alzheimer's disease and we are driving an exciting HIV drug candidate and two strong anti-cancer drug candidates toward human clinical trials."

gruß
sertralin19


 

In den letzten Tagen gab es mehrere SEC-Filings zu Insider-Käufen bei Myriad:

http://10kwizard.ccbn.com/...=336633&AL=FF0000&VL=669933&SC=ON&DF=OFF

Sehr erfreulich ist, dass die Insider gerade jetzt einsteigen, da die seit über einem Jahr entstandene Boden-W-Formation kurz vor Ihrer Vollendung steht. Eine Auflösung nach oben scheint also nicht nur mir wahrscheinlich...

Gruß
sertralin19  

Ohne Worte:




Gruß
sertralin19
 

Myriad Genetics (ticker: MYGN, exchange: NASDAQ) News Release - 19-Feb-2004


--------------------------------------------------
Myriad Genetics Improves Patient Access to Predictive Medicine

SALT LAKE CITY, Feb. 19 /PRNewswire-FirstCall/ -- Myriad Genetics, Inc. (Nasdaq: MYGN), announced today that it has substantially simplified access to its predictive medicine products, making the Company's potentially life-saving genetic technology more readily available to the more than 200 million Americans whose insurers cover predictive medicine tests.

Several major insurers, including UnitedHealthcare, have recently adopted simplified, streamlined processes for coverage and reimbursement. Their new contracts with Myriad provide predictive medicine services to their eligible members, using expedient dedicated mechanisms for reimbursement. Separately, Medicare coverage has been clarified and improved to accommodate more individuals with family histories of breast or ovarian cancer than were previously considered.

"We are committed to getting our predictive medicine products into the hands of the individuals whose lives can substantially benefit from their use," said Gregory Critchfield, M.D., President of Myriad Genetic Laboratories, Inc. "Disease prediction, prevention and treatment are the cornerstones of the foundation upon which Myriad is built. We believe that ready access to these products will stimulate utilization resulting in patients living longer, healthier lives."

While most insurance companies and HMOs already reimburse predictive medicine testing, setting coverage criteria and paying for testing as submissions are received can be a complex and cumbersome process for the patient. Myriad is helping make this process faster and easier through its contracting process with large insurers to provide predictive medicine testing. In this way, patient coverage criteria are set in advance, reimbursement rates are established and physicians throughout the healthcare system are notified of the coverage. This process also builds physician awareness of Myriad's predictive medicine tests and increases the likelihood that physicians will order the tests when they encounter patients who are at risk. Individuals at risk of cancer and their physicians can now rapidly determine whether they meet the coverage criteria and have the test performed, eliminating the financial concerns that previously complicated their medical decision-making.

Insurer contracting by Myriad is one of several prongs in a coordinated program to make predictive medicine easier to understand, easier to access and easier to have reimbursed, so that those people at risk of cancer can have the information they need to better manage their healthcare. Myriad is tearing down the barriers that hinder access to highly valuable new life-saving medical technologies. Through substantial efforts in education and awareness, physicians and their patients are now embracing these tools, as they gain experience with the decision-making power that is provided by predictive medicine. For individuals diagnosed with cancer, medical and surgical decision-making can be enhanced, so that they can focus on the business of getting the care they need, and move forward with their lives. Additionally, recent studies have shown that Myriad's predictive medicine products identify a greater risk to the patient than previously thought. In the case of breast cancer and ovarian cancer, for example, the lifetime risk is now placed at 82% and 54% respectively, for carriers of a BRCA1 or BRCA2 mutation.

Removing barriers and building alliances, Myriad is expanding the reach of predictive medicine to benefit all of those at risk of breast cancer, ovarian cancer, endometrial cancer, colon cancer and melanoma. Myriad believes that these programs are making a significant impact on the acceptance of its products in the medical community. Myriad's predictive medicine revenues grew to a record $10.4 million in its latest financial quarter, a 28% increase compared with the same period in the prior year.

Gruß
Sertralin19

 

Gruß
Sertralin19
 

Erstes Kursziel: USD 25. Werden im späteren Verlauf USD 30 überschritten, ist der Weg nach oben erst mal frei. Das kann dann alles sehr schnell gehen...

Gruß
Sertralin19
 

- MACD setzt bei zunehmendem RSI zum Schnitt nach oben an
- Kurs an wichtiger Marke: Neues High steht vor der Tür
- Test der 38er GDL erfolgreich
- Durchbruch des oberen Bollingerbandes steht kurz bevor

Und vor allem: Kein Mensch hier im Forum scheint sich für MYD zu interessieren. Das stimmt mich besonders zuversichtlich.

Gruß
sertralin19  

Mit dem gestrigen Schlusskurs bei USD 17,71 hat Myriad den seit Herbst 2000 andauernden, übergeordneten Downtrend verlassen. Alle o.g. Signale stehen jetzt endgültig auf BUY. Go, Myriad, go!

Gruß
sertralin19, offensichtlich der einzige MYDianer im Forum...  

...was bin ich froh, dass ich das Ding tapfer gehalten und nachgekauft hab...

weiter so, Myriad, go on!

Gruß
sertralin19  

Myriad Genetics (ticker: MYGN, exchange: NASDAQ) News Release - 4-May-2004


--------------------------------------------------
Myriad Genetics Reports Results for Third Quarter of Fiscal 2004

- Predictive Medicine Revenues Increase to a Record $11.7 Million -

SALT LAKE CITY, May 4 /PRNewswire-FirstCall/ -- Myriad Genetics, Inc. (Nasdaq: MYGN) today reported consolidated financial results for the third quarter of fiscal 2004 and the nine months ended March 31, 2004.

For the third fiscal quarter, ended March 31, 2004, predictive medicine product revenues increased to $11.7 million from $9.3 million in the same quarter of the prior year, an increase of 26%. Third quarter predictive medicine product revenues also demonstrated strong sequential quarterly growth of 12%, or $1.3 million, over the second quarter of fiscal 2004. The increased revenue resulted from continued growth in demand for our predictive medicine products, which is due in part to increased sales and marketing efforts and the recent publication of studies supporting the clinical utility of our products. The Company ended the quarter in strong financial condition with no debt and over $99 million in cash, cash equivalents and marketable investment securities.

Gross profit margins on predictive medicine product revenues continue to improve. For the third fiscal quarter of 2004, these profit margins rose to 68% compared with 64% gross profit margins one year ago, in the third quarter of fiscal year 2003. The Company believes that the profit margins for predictive medicine products are not only exceptional in the molecular diagnostic industry today but have the potential to increase further, eventually into the mid-70% range, resulting in margins comparable to those delivered by many pharmaceutical companies.

Myriad invests significant resources in the research and development of drugs that include those that may alter the course of Alzheimer's disease, offer new options for AIDS patients and provide more effective treatments for cancer patients. The Company is committed to a period of resource investment with the potential for substantial reward upon achieving revenues from therapeutic products that treat these diseases in the future. In the interim, Myriad's profitable and growing business in predictive medicine is important in offsetting a portion of the costs of drug development. This conservative but strong commitment to investment in drug development by Myriad resulted in a net loss for the third quarter of fiscal year 2004 of $10.7 million ($0.39 basic and diluted loss per share).

"Myriad's third quarter results demonstrate continued strong revenue growth and improving profit margins in our predictive medicine business," said Peter Meldrum, President and Chief Executive Officer for Myriad Genetics, Inc. "We have also achieved substantial progress in our drug development programs for the treatment of Alzheimer's disease, cancer and AIDS."

Myriad's drug candidate for the treatment of Alzheimer's disease, Flurizan(TM) (R-flurbiprofen) is being studied in a Phase II clinical trial in more than 200 patients with mild to moderate Alzheimer's disease. The one-year study period of the Phase II trial is expected to be completed in the clinic during the first calendar quarter of 2005. The trial is designed to demonstrate the efficacy of Flurizan in the slowing as well as the potential reversal of cognitive decline in Alzheimer's disease patients, by lowering the toxic peptide Abeta42, the primary culprit in Alzheimer's disease and a major component of senile plaques in the brain. Myriad believes that Flurizan has the potential to become the first drug on the market for Alzheimer's disease that can alter the underlying course of the disease.

Myriad also has an ongoing Phase II/III human clinical trial of R-flurbiprofen in prostate cancer. In addition, the Company has a pipeline of advanced pre-clinical compounds that it is moving towards human clinical testing. These include the drug candidates MPC-6827 for pancreatic cancer, MPI-176716 for ovarian cancer, MPI-49839 for the treatment of AIDS and MPC-4505 for chemotherapy-induced emesis (nausea and vomiting associated with cancer chemotherapy).

Highlights of the Third Quarter of Fiscal 2004

Myriad achieved significant progress on many fronts during the third quarter, including:

      *  Expansion of our strategic alliance with Abbott Laboratories into
         pharmacogenetics,

      *  Release of preclinical animal data on MPI-176716, the Company's
         candidate drug for treatment of ovarian cancer,

      *  Presentation of data on MPC-6827, at the American Association for
         Cancer Research, in successfully causing tumor remission in animal
         models of pancreatic cancer and other cancers,

      *  Improvement of patient access to our predictive medicine products,

      *  Addition of two new members to our Board of Directors, Dr. Dennis
         Langer, former Senior Vice President with Glaxo SmithKline in R&D
         Project and Portfolio Management and Dr. John Henderson, former Vice
         President of the Pfizer Pharmaceuticals Group.

Na das schaut doch recht ordentlich aus!!!

Gruß
sertralin19

 

       
     


Ein Traum von einem Doppelboden zeichnet sich derzeit im Langfristchart ab. Könnte den finalen Ausbruch einleiten. Das Diagnostikageschäft läuft scheint´s recht gut, so zumindest der Quartalsbericht (s. www.myriad.com).

Zuversichtlicher Gruß

sertralin19  

Myriad Genetics, Inc. Reports Results for First Quarter of Fiscal 2005

- Predictive Medicine Revenues Up 79% Over First Quarter Last Year -

SALT LAKE CITY, Nov. 9 /PRNewswire-FirstCall/ -- Myriad Genetics, Inc. (Nasdaq: MYGN) today reported financial results for the first quarter of fiscal 2005. For this three-month period ended September 30, 2004, predictive medicine revenues increased to $14.4 million from $8.1 million for the same quarter of the prior year, an increase of 79%.

Compared with the fourth quarter of fiscal 2004, predictive medicine revenues were up $1.3 million, or 10%. Greater demand for the Company's predictive medicine products resulted from increased sales and marketing efforts coupled with recent publications that indicate enhanced utility of the BRACAnalysis(R) product in medical care. These publications include a study demonstrating the greater value of MRI screening as compared with conventional mammography among women with a mutation in a BRCA breast cancer gene.

The gross profit margin on the predictive medicine business was 71% for the first quarter of fiscal 2005, compared with 66% for the first quarter of the prior year. This gross profit margin increase resulted from technology improvements, efficiency gains and the realization of recent price increases in the predictive medicine business.

Total revenues for the first quarter were $16.7 million, up 22% from the same quarter of the prior year. Research revenues were $2.3 million for the first quarter of fiscal 2005, compared with approximately $2 million for each of the previous two quarters. Research revenues decreased 59% from the first quarter of fiscal 2004, reflecting the Company's continued emphasis on internal drug development programs and reduced emphasis on external research collaborations.

Research and development expenses for the three months ended September 30, 2004 were $13.1 million compared with $13.0 million for the same three-month period in the prior year. This investment in research and development was largely composed of clinical trial expenses associated with the continuing development of Myriad's therapeutic products in prostate cancer and Alzheimer's disease and was partially offset by a decrease in research expense associated with external collaborations.

The net loss for the first quarter of fiscal 2005 was $10.0 million, or $0.33 per share, compared with a net loss of $10.5 million, or $0.37 per share for the previous quarter, ended June 30, 2004. As of September 30, 2004, Myriad remains in strong financial condition, with approximately $130 million in cash, cash equivalents and marketable investment securities. The Company has no debt or convertible securities.

"We are pleased with the strong growth in product revenues during the quarter," said Peter Meldrum, President and Chief Executive Officer of Myriad Genetics, Inc. "In addition, the progress we have achieved in advancing our preclinical drug candidates has kept us on track toward submitting two new IND applications before the end of this calendar year."

Conference Call and Webcast

A conference call with Company management will be held today at 10:00 a.m. Eastern Time with investors and media to discuss these results and recent events at the Company. Between 9:45 a.m. and 10:00 a.m., the dial-in number for domestic callers is (888) 589-2821. International callers may dial (706) 634-2173. A replay of the call will be made available for one week, beginning two hours after the call, and can be accessed by dialing (800) 642-1687 or (706) 645-9291, and entering conference ID #1770098. The audio conference call can also be accessed on the Web at www.myriad.com

Myriad Genetics, Inc. is a leading biopharmaceutical company focused on the development of novel healthcare products. The Company develops and markets proprietary predictive medicine products, and is developing and intends to market a number of promising therapeutic products that address large potential markets. Myriad's news and other information are available on the Company's Web site at www.myriad.com.

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward looking statements are based on management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those set forth or implied by forward-looking statements. These statements include, but are not limited to increased demand for the Company's predictive medicine products, strong growth in product revenues, continued publications on the importance of the BRACAnalysis(R) product, the Company's continued emphasis on internal drug development programs and reduced emphasis on external research collaborations, continued development of the Company's therapeutic products in clinical trials and the expenses associated therewith and the targeted submission of two IND applications before the end of this calendar year, uncertainties as to the extent of future government regulation of Myriad Genetics' business; risks and uncertainties as to whether Myriad Genetics and its collaborators will be successful in developing, and obtaining regulatory approval for, and commercial acceptance of, therapeutic compounds; the risk that markets will not exist for therapeutic compounds that Myriad Genetics develops or if such markets exist, that Myriad Genetics will not be able to sell compounds which it develops at acceptable prices; the risk that the Company will not be able to sustain revenue growth for its predictive medicine business and products, and risks associated with preclinical development activities that could cause delays in, or even prevent, planned IND applications. These and other risks are identified in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the fiscal year ended June 30, 2004. All information in this press release is as of November 9, 2004, and Myriad undertakes no duty to update this information unless required by law.

BRACAnalysis is a registered trademark of Myriad Genetics, Inc. in the United States and certain other foreign countries.


                   MYRIAD GENETICS, INC. AND SUBSIDIARIES
        CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited)

    (in thousands, except per share amounts)         Three Months Ended
                                               Sep. 30, 2004   Sep. 30, 2003
    REVENUES:

      Predictive medicine revenue                 $14,429          $8,064
      Research revenue                              2,281           5,079
      Related party research revenue                   --             529
        Total research revenue                      2,281           5,608
        Total revenues                             16,710          13,672

    COSTS AND EXPENSES:

      Predictive medicine cost of revenue           4,239           2,758
      Research and development expense             13,132          12,974
      Selling, general and
       administrative expense                       9,956           8,108
        Total costs and expenses                   27,327          23,840

        Operating loss                            (10,617)        (10,168)

   Other income (expense):
     Interest income                                  632             569
     Other                                             (7)            (10)
                                                      625             559
     Net loss                                     ($9,992)        ($9,609)

     Basic and diluted loss per share              ($0.33)         ($0.35)

     Basic and diluted weighted
      average shares outstanding                   30,649          27,087


             Condensed Consolidated Balance Sheets (Unaudited)

    (In thousands)                            Sep. 30, 2004   Jun. 30, 2004
    Cash, cash equivalents, and
     marketable investment securities            $129,589        $141,839
    Trade receivables, net                         16,627          13,994
    Other receivables                               1,452             554
    Prepaid expenses                                5,804           7,279
    Equipment and leasehold improvements, net      16,793          17,339
    Other assets                                    7,213           7,351
      Total assets                               $177,478        $188,356

    Accounts payable and accrued liabilities      $12,704         $13,871
    Deferred revenue                                1,157           1,209
    Stockholders' equity                          163,617         173,276
      Total liabilities and
       stockholders' equity                      $177,478        $188,356


SOURCE Myriad Genetics, Inc.
11/09/2004
CONTACT: William A. Hockett, Vice President of Corporate Communications of Myriad Genetics, Inc., +1-801-584-3600, bhockett@myriad.com
Web site: http://www.myriad.com


In einem Jahr steht MYD wieder bei 60 $, jede Wette.
Go Myriad, go!

Gruß
Sertralin19


 

... und danach geht´s dann dahin.

Gruß
Sertralin19


 

Und weiter geht es! Bereits den 2. Tag in Folge hat MYD über 20 $ geschlossen, das gab´s zuletzt Ende 2002. Diese Marke sollte nachhaltig zurückerobert werden, dann ist der Weg erst mal frei bis 25 / 38 / 50 / 70 Dollar. MYD hat viel nachzuholen. Ich rechne weiterhin mit einer recht volatilen Entwicklung in den nächsten Wochen und Monaten,auch kurzzeitige Rückfälle unter die 20 $ können noch drin sein. Diese Marke sollte aber rasch zurückerobert werden, um das hier dargestellte, positive Szenarium nicht zu gefährden. M. E. könnte MYD in 2005 eine ähnliche Entwicklung nehmen wie MOR im Tecdax. MYD ist jedenfalls mein Top-Tip für eine simple buy&hold-Strategie in 2005. Kurse um 20 $ sind auf jeden Fall Kaufkurse.

Gruß
sertralin19  

... M. E. könnte MYD in 2005 eine ähnliche Entwicklung nehmen wie MOR im Tecdax
(gemeint ist: wie MOR im Jahr 2004)

Gruß
sertralin19  

ANALYSE: Piper Jaffray bewertet Myriad mit 'Outperform' - 'Top Pick 2005'
 
NEW YORK (dpa-AFX) - Piper Jaffray hat die Aktie des Biotechnologieunternehmens Myriad Genetics   von "Marketperform" auf "Outperform" herauf gestuft. Der Titel wurde in einer am Montag in New York vorgelegten Studie als ein "Top Pick" für 2005 bezeichnet. Analyst Edward Tenthoff nannte als Hauptgrund die Ergebnisse einer "Phase II"-Studie für das Medikament Flurizan, einem potenziellen Alzheimer-Mittel.

Myriad werde in den kommenden Monaten weitere wichtige Ergebnisse über Studien für neue Medikamente vorlegen, hieß es ergänzend. Auch in anderen Sparten werde sich das Wachstum von Myriad als überdurchschnittlich erweisen, hieß es von Piper Jaffray.

Eingestuft mit "Outperform" geht Piper Jaffray davon aus, dass sich die Aktie in den nächsten zwölf Monaten besser als der S&P-500-Index  oder der Russell-2000-Index entwickeln wird./FX/mnr/fat


Habe ich doch schon die ganze Zeit gesagt!

Gruß
sertralin19
 

Myriad Genetics Submits IND on MPC-6827 Cancer Drug

- Phase I Clinical Trial in Patients With Solid Tumors -
SALT LAKE CITY, Dec 9, 2004 /PRNewswire-FirstCall via COMTEX/ -- Myriad Genetics, Inc. (Nasdaq: MYGN), announced today that it has submitted an Investigational New Drug (IND) application to the FDA to begin a Phase I clinical study with its pro-apoptotic cancer drug candidate, MPC-6827.

The study is designed to evaluate the safety and pharmacokinetic profile of MPC-6827 in patients with advanced solid tumors, in an escalating dose regimen. In preclinical testing, MPC-6827 has been equally active against multiple drug resistant cancers as with susceptible tumors, unlike many of the current options in cancer chemotherapy, a limitation that represents a significant unmet medical need.

"MPC-6827 has demonstrated the ability to inhibit tumor growth in preclinical testing, with activity in animal models of human melanoma and cancers of the ovary, breast, prostate, colon and pancreas," said Adrian Hobden, Ph.D., President of Myriad Pharmaceuticals, Inc. "This IND submission is a major milestone in the development of this new drug candidate, and we are excited about the possibility of demonstrating the same activity in cancer patients that we have found in preclinical testing with MPC-6827."

In preclinical testing, MPC-6827 was demonstrated to be significantly more active than the relevant standard-of-care chemotherapy drug at inhibiting tumor growth in xenograft models of cancer. MPC-6827 was shown to be more effective than doxorubicin in breast cancer, gemcitibine in pancreatic cancer, irinotecan in colon cancer, carboplatin in ovarian cancer and demonstrated a substantial inhibition of prostate cancer tumor growth, for which there is no currently recognized standard of care.

Cancer cells may become resistant to chemotherapy through a cellular function that actively excretes drug from the cell. The function is carried out by multiple drug resistance (MDR) pumps and is the primary cause of cancer's resistance to marketed drugs such as paclitaxel and vinblastine. MPC-6827 was tested, in parallel with vinblastine and docetaxel, to determine its relative susceptibility to MDR pumps. MPC-6827 was shown to be equally effective in anti-cancer activity against the MDR cell lines tested, suggesting that the drug candidate is not a substrate for MDR pumps. In contrast, the potency of the currently marketed drugs was substantially reduced against these MDR cell lines, requiring approximately 20 to 70 times more drug in the case of docetaxel and 165 to 1,200 times more drug for vinblastine, to reach the same level of activity that was measured in non-MDR cells.

"MPC-6827 is Myriad's third clinical drug development program and we are on schedule to move a fourth program into the clinic in the very near future," said Peter Meldrum, President and Chief Executive Officer of Myriad Genetics, Inc. "Our drug candidates address Alzheimer's disease and multiple types of cancer, all diseases for which we believe there is significant unmet medical need and very large potential markets."

MPC-6827 was identified by Myriad researchers from a family of compounds acquired from Maxim Pharmaceuticals, Inc. All chemistry, lead optimization and preclinical development on the compound was performed by Myriad or for Myriad under its direction.

Myriad's Other Clinical Drug Development Programs

FLURIZAN(TM) (MPC-7869) is Myriad's investigative drug for Alzheimer's disease and prostate cancer. This drug candidate is being investigated in a large, well-controlled Phase II trial in Alzheimer's disease that is expected to complete its clinical study period in the first quarter of calendar 2005. It is also under study in a large, well-controlled, 3-year, Phase II/III clinical trial in prostate cancer, which is expected to complete its clinical study period in the second calendar quarter of 2006. Myriad is also developing a broad range of pre-clinical compounds, with three late-stage programs in the fields of cancer, HIV and emesis (cancer-induced nausea and vomiting) that we believe will reach the human clinical trial stage during the next 12 months.

Myriad Genetics, Inc. is a biopharmaceutical company focused on the development of novel healthcare products. The Company develops and markets predictive medicine products, and is developing and intends to market therapeutic products. Myriad's news and other information are available on the Company's Web site at www.myriad.com.

Passen zur Nachricht knackt MYD in USA die 22 $ -Marke.

Und das ist m. E. erst der Anfang.

Gruß
sertralin19  

für MYGNianer. Hat heute gute 8 % gemacht:

NASDAQ  23,91  14.12.04  22:00  34,22 Mio.  5.031  

mit seit Ewigkeiten nicht mehr gesehenen Umsätzen im strammen Aufwärtsschub. Das erste Wetterleuchten weist auf den kommenden Aufwind. Seit dem ersten Posting sind es jetzt gute 50 % plus, die MYGN in diesem Jahr gemacht hat.

Niemand außer mir hat je etwas in diesem Thread gepostet. Und es gibt wahrlich schlechtere Besprechungen in diesem Forum. Gerade das stimmt mich auch weiterhin optimistisch, dass die meisten noch nicht einmal ahnen, dass die MYGN auch für sie gewinnbringend sein könnte.

mfg
sertralin19



   

Myriad Genetics: Buy

23.12.2004 - Die Experten von First Albany haben die Aktie des Biotech-Unternehmens Myriad Genetics mit „buy“ eingestuft und damit ihre bisherige Haltung bekräftigt. Das Kursziel für den Titel liegt bei 33 Dollar.

mfg
sertralin19
 

Myriad Genetics neues Kursziel


Die Analysten der UBS stufen die Aktie von Myriad Genetics (ISIN US62855J1043/ WKN 897518) unverändert mit "buy" ein. Das Kursziel werde indes von 25 auf 28 USD nach oben gesetzt. Bislang habe die Bewertung der Aktie auf dem stabilen und wachsenden prädiktiven Medizingeschäft basiert. Mit der zunehmenden Transparenz von Myriad`s Pipeline und dem bevorstehenden Abschluss einer Schlüsselstudie für Flurizan zur Behandlung von Alzheimer würden sich die therapeutischen Anstrengungen des Unternehmens nun in einem Stadium befinden, wo man sie angemessen bewerten könne. Vor diesem Hintergrund sprechen die Analysten der UBS für die Aktie von Myriad Genetics weiterhin eine Kaufempfehlung aus.  
Quelle: AKTIENCHECK.DE

Gruß
sertralin19